严重急性呼吸综合征冠状病毒 2 感染和肺癌患者：白细胞介素 17 靶向治疗的潜在作用。
Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy.
机构信息
Istituto Oncologico della Svizzera Italiana, Università della Svizzera Italiana, Bellinzona, Switzerland.
出版信息
J Thorac Oncol. 2020 Jul;15(7):e101-e103. doi: 10.1016/j.jtho.2020.04.015. Epub 2020 Apr 27.
Abstract
The coronavirus disease 2019 outbreak is evolving rapidly worldwide. The lungs are the target of the primary infection and patients with lung cancer seem to have a poor prognosis. To our knowledge, this is the first reported investigation of a possible role of interleukin-17 target therapy in patients with lung cancer and concomitant severe acute respiratory syndrome-coronavirus-2 infection.
摘要
2019 冠状病毒病疫情在全球迅速蔓延。肺部是原发感染的靶器官，肺癌患者的预后似乎较差。据我们所知，这是首次报道白介素-17 靶向治疗在肺癌合并严重急性呼吸综合征冠状病毒 2 感染患者中的可能作用的研究。
相似文献
1
Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy.严重急性呼吸综合征冠状病毒 2 感染和肺癌患者：白细胞介素 17 靶向治疗的潜在作用。
J Thorac Oncol. 2020 Jul;15(7):e101-e103. doi: 10.1016/j.jtho.2020.04.015. Epub 2020 Apr 27.
2
Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.β2-肾上腺素能通路能否成为抗击 SARS-CoV-2 炎症风暴综合征的新靶点？——癌症带来的启示。
Front Immunol. 2020 Sep 30;11:588724. doi: 10.3389/fimmu.2020.588724. eCollection 2020.
3
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.COVID-19 患者的激肽释放酶-激肽系统阻断治疗以预防急性呼吸窘迫综合征。
Elife. 2020 Apr 27;9:e57555. doi: 10.7554/eLife.57555.
4
A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.针对 SARS-CoV-2 感染中 Th17 细胞和 IL-17A 的治疗策略。
J Immunol. 2020 Aug 15;205(4):892-898. doi: 10.4049/jimmunol.2000554. Epub 2020 Jul 10.
5
Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者急性呼吸窘迫综合征期间的炎症反应细胞
Ann Intern Med. 2020 Sep 1;173(5):402-404. doi: 10.7326/L20-0227. Epub 2020 Apr 13.
6
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.癌症免疫治疗学会对 COVID-19 相关全身炎症反应中白细胞介素-6 信号转导的调控观点。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000930.
7
Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".COVID-19 中的细胞因子风暴：“当你走出风暴时，你将不再是走进来的那个人”。
Front Immunol. 2020 Sep 2;11:2132. doi: 10.3389/fimmu.2020.02132. eCollection 2020.
8
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?白细胞介素-17能否成为治疗和/或管理新型冠状病毒肺炎相关呼吸综合征的新治疗靶点？
Pharmacol Res. 2020 Jun;156:104791. doi: 10.1016/j.phrs.2020.104791. Epub 2020 Apr 14.
9
Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.SARS-CoV-2 激活的肥大细胞释放组织胺，增加白细胞介素-1 水平，导致 COVID-19 中的细胞因子风暴和炎症反应。
J Biol Regul Homeost Agents. 2020;34(5):1629-1632. doi: 10.23812/20-2EDIT.
10
Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.雷洛昔芬和巴多昔芬可能是预防 COVID-19 相关细胞因子风暴、ARDS 和死亡率的有希望的候选药物。
In Vivo. 2020 Sep-Oct;34(5):3027-3028. doi: 10.21873/invivo.12135.
引用本文的文献
1
Notch4 regulatory T cells and SARS-CoV-2 viremia shape COVID19 survival outcome.Notch4调节性T细胞和SARS-CoV-2病毒血症影响COVID-19的生存结果。
Allergy. 2025 Feb;80(2):557-569. doi: 10.1111/all.16333. Epub 2024 Oct 3.
2
Outcomes of Patients Undergoing Major Surgery for Cancer with COVID-19 in the Postoperative Period.新冠肺炎患者癌症大手术后的术后结局
Indian J Surg Oncol. 2023 Dec;14(4):876-880. doi: 10.1007/s13193-023-01797-7. Epub 2023 Jul 7.
3
The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target.Th-17 细胞和 IL-17 在乳腺癌转移中的作用：作为预后和治疗靶点的一种手段。
Front Immunol. 2023 Mar 13;14:1094823. doi: 10.3389/fimmu.2023.1094823. eCollection 2023.
4
Global Effect of COVID-19 Pandemic on Cancer Patients and its Treatment: A Systematic Review.2019年冠状病毒病大流行对癌症患者及其治疗的全球影响：一项系统综述
Clin Complement Med Pharmacol. 2022 Dec;2(4):100041. doi: 10.1016/j.ccmp.2022.100041. Epub 2022 Apr 25.
5
[Translated article] Practical Guide to New Treatments for SARS-CoV-2 Infection in Dermatology Patients Being Treated With Common Immunomodulators.[翻译文章] 正在接受常用免疫调节剂治疗的皮肤科患者中新型SARS-CoV-2感染治疗实用指南。
Actas Dermosifiliogr. 2023 Jan;114(1):T49-T53. doi: 10.1016/j.ad.2022.07.024. Epub 2022 Nov 8.
6
Exploration of the Mechanism of Lianhua Qingwen in Treating Influenza Virus Pneumonia and New Coronavirus Pneumonia with the Concept of "Different Diseases with the Same Treatment" Based on Network Pharmacology.基于网络药理学以“异病同治”理念探讨连花清瘟治疗流感病毒肺炎及新型冠状病毒肺炎的机制
Evid Based Complement Alternat Med. 2022 Feb 8;2022:5536266. doi: 10.1155/2022/5536266. eCollection 2022.
7
The signal pathways and treatment of cytokine storm in COVID-19.新型冠状病毒肺炎中细胞因子风暴的信号通路与治疗策略。
Signal Transduct Target Ther. 2021 Jul 7;6(1):255. doi: 10.1038/s41392-021-00679-0.
8
Immune mediating molecules and pathogenesis of COVID-19-associated neurological disease.COVID-19 相关神经疾病的免疫介导分子和发病机制。
Microb Pathog. 2021 Sep;158:105023. doi: 10.1016/j.micpath.2021.105023. Epub 2021 Jun 4.
9
Cell-mediated immunity to SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的细胞介导免疫
Pediatr Investig. 2020 Dec 28;4(4):281-291. doi: 10.1002/ped4.12228. eCollection 2020 Dec.
10
Safety of secukinumab treatment in COVID-19 affected psoriatic patients.司库奇尤单抗治疗新冠病毒感染的银屑病患者的安全性
Dermatol Ther. 2021 Jan;34(1):e14710. doi: 10.1111/dth.14710. Epub 2021 Jan 3.
本文引用的文献
1
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?COVID-19：慢性炎症性疾病中细胞因子靶向治疗的风险？
Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.
2
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.COVID-19 细胞因子风暴中的 TH17 反应：JAK2 抑制剂 Fedratinib 的一个新靶点。
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11.
3
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
4
IL-17 stimulates the expression of CCL2 in cardiac myocytes via Act1/TRAF6/p38MAPK-dependent AP-1 activation.IL-17 通过 Act1/TRAF6/p38MAPK 依赖性 AP-1 激活刺激心肌细胞中 CCL2 的表达。
Scand J Immunol. 2020 Jan;91(1):e12840. doi: 10.1111/sji.12840. Epub 2019 Nov 10.
5
Role of interleukin-17 in acute myocardial infarction.白细胞介素-17 在急性心肌梗死中的作用。
Mol Immunol. 2019 Mar;107:71-78. doi: 10.1016/j.molimm.2019.01.008. Epub 2019 Jan 17.
6
Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice.抗白细胞介素-17对脂多糖诱导的小鼠急性肺损伤的保护作用
Front Pharmacol. 2018 Oct 4;9:1021. doi: 10.3389/fphar.2018.01021. eCollection 2018.
7
The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus.IL-17/Th17 细胞在 1 型和 2 型糖尿病中的潜在致病作用。
Biomed Pharmacother. 2018 May;101:287-292. doi: 10.1016/j.biopha.2018.02.103. Epub 2018 Feb 27.
8
IL-17A promotes the formation of deep vein thrombosis in a mouse model.IL-17A 促进小鼠模型中深静脉血栓的形成。
Int Immunopharmacol. 2018 Apr;57:132-138. doi: 10.1016/j.intimp.2018.02.006. Epub 2018 Feb 24.
9
Effects of Anti-IL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS.抗白细胞介素-17对脂多糖加重的哮喘实验模型中炎症、重塑和氧化应激的影响
Front Immunol. 2018 Jan 5;8:1835. doi: 10.3389/fimmu.2017.01835. eCollection 2017.
10
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.靶向肿瘤微环境：与癌症类型相关的白细胞介素-17的促肿瘤作用
Int J Mol Sci. 2016 Aug 30;17(9):1433. doi: 10.3390/ijms17091433.
Zotero 插件